Aging
Navigate
Back to articleFigure 5(5 of 7)
100%
Figure 5
Figure 5.Effect of STO-609 and Compound C on Cell Viability of rLSECs. rLSECs were treated with STO-609 (0, 1, 5, 10, 15 and 20 μg/ml) and Compound C (0, 1, 5, 10, 15 and 20 μM) for 0.5, 1, 6, 12, 24 or 48 h, respectively. Cell viability was determined by MTT test. All data is expressed as mean ± SD. P<0.05 versus control. (A) The effect of STO-609 on rLSEC viability (control is untreated group). (B) The effect of STO-609 on rLSEC viability (control is untreated group). All data is expressed as mean ± SD. from three independent experiments. P < 0.05 versus control.
Figure 5 — CTRP13 attenuates the expression of LN and CAV-1 Induced by high glucose via CaMKK&#x3B2;/AMPK pathway in rLSECs | Aging